MA27676A1 - 2-amino-6-(2-substitue-4-phenoxy)-substitue-pyridines, procede pour leur preparation et compositions pharmaceutiques les contenant - Google Patents

2-amino-6-(2-substitue-4-phenoxy)-substitue-pyridines, procede pour leur preparation et compositions pharmaceutiques les contenant

Info

Publication number
MA27676A1
MA27676A1 MA24958A MA24958A MA27676A1 MA 27676 A1 MA27676 A1 MA 27676A1 MA 24958 A MA24958 A MA 24958A MA 24958 A MA24958 A MA 24958A MA 27676 A1 MA27676 A1 MA 27676A1
Authority
MA
Morocco
Prior art keywords
substituted
preparation
pharmaceutical compositions
compositions containing
pyridines
Prior art date
Application number
MA24958A
Other languages
English (en)
Inventor
John Adams Lowe Iii
Jolanta Nowakowski
Robert Alfred Volkmann
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MA27676A1 publication Critical patent/MA27676A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

DEPOSANT Société dite : PFIZER PRODUCTS INC. REVENDICATION DE PRIORITES US 10/02/1997 60/037533 2-amino-6-(2-substitué-4-phénoxy)-substitué-pyridines, procédé pour leur préparation et compositions pharmaceutiques les contenant L'invention concerne des composés de formule dans laquelle G, R1 et R2 représentent divers radicaux. Elle concerne également un procédé pour leur préparation et des compositions pharmaceutiques les contenant. Application : utilisation dans le traitement et la prévention d'affections du système nerveux central et d'autres maladies.
MA24958A 1997-02-10 1998-02-09 2-amino-6-(2-substitue-4-phenoxy)-substitue-pyridines, procede pour leur preparation et compositions pharmaceutiques les contenant MA27676A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3753397P 1997-02-10 1997-02-10

Publications (1)

Publication Number Publication Date
MA27676A1 true MA27676A1 (fr) 2006-01-02

Family

ID=21894849

Family Applications (1)

Application Number Title Priority Date Filing Date
MA24958A MA27676A1 (fr) 1997-02-10 1998-02-09 2-amino-6-(2-substitue-4-phenoxy)-substitue-pyridines, procede pour leur preparation et compositions pharmaceutiques les contenant

Country Status (44)

Country Link
US (2) US20010007873A1 (fr)
EP (1) EP0958282B1 (fr)
JP (1) JP3505189B2 (fr)
KR (1) KR100460399B1 (fr)
CN (3) CN1246848A (fr)
AP (1) AP833A (fr)
AR (1) AR011117A1 (fr)
AT (1) ATE271544T1 (fr)
AU (1) AU744313B2 (fr)
BG (1) BG103633A (fr)
BR (1) BR9811093A (fr)
CA (1) CA2277990C (fr)
CO (1) CO4920225A1 (fr)
CZ (1) CZ292135B6 (fr)
DE (1) DE69825147T2 (fr)
DK (1) DK0958282T3 (fr)
DZ (1) DZ2414A1 (fr)
EA (1) EA003834B1 (fr)
ES (1) ES2224354T3 (fr)
GT (1) GT199800032A (fr)
HN (1) HN1998000030A (fr)
HR (1) HRP980069A2 (fr)
HU (1) HUP0000762A3 (fr)
IL (1) IL130898A0 (fr)
IS (1) IS5118A (fr)
MA (1) MA27676A1 (fr)
MY (1) MY120976A (fr)
NO (1) NO314803B1 (fr)
NZ (2) NZ518345A (fr)
OA (1) OA11084A (fr)
PA (1) PA8446301A1 (fr)
PE (1) PE58599A1 (fr)
PL (1) PL335161A1 (fr)
PT (1) PT958282E (fr)
SI (1) SI0958282T1 (fr)
SK (1) SK101199A3 (fr)
TN (1) TNSN98024A1 (fr)
TR (1) TR199901917T2 (fr)
TW (1) TW458969B (fr)
UA (1) UA64740C2 (fr)
UY (1) UY24881A1 (fr)
WO (1) WO1998034919A1 (fr)
YU (1) YU35699A (fr)
ZA (1) ZA981017B (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010049379A1 (en) 1997-08-27 2001-12-06 Lowe John Adams 2-aminopyridines containing fused ring substituents
HRP20000825A2 (en) * 1998-06-03 2001-12-31 Pfizer Prod Inc 2-aminopyridines containing fused ring substituents as nitric oxide synthase inhibitors
HRP20010099A2 (en) * 1998-08-11 2002-02-28 Pfizer Prod Inc New pharmaceutical uses for nos inhibitors
SE9803710L (sv) 1998-09-25 2000-03-26 A & Science Invest Ab Användning av vissa substanser för behandling av nervrotsskador
US7115557B2 (en) 1998-09-25 2006-10-03 Sciaticon Ab Use of certain drugs for treating nerve root injury
CN1341099A (zh) 1999-02-25 2002-03-20 辉瑞产品公司 含有稠合环取代基的2－氨基吡啶
FR2812635B1 (fr) * 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
GB0019006D0 (en) * 2000-08-04 2000-09-20 Astrazeneca Ab Novel compounds
US20030232739A1 (en) * 2001-08-15 2003-12-18 Pfizer Inc. Pharmaceutical combinations comprising a NOS inhibitor and an NMDA receptor antagonist
US20030045449A1 (en) * 2001-08-15 2003-03-06 Pfizer, Inc. Pharmaceutical combinations for the treatment of neurodegenerative diseases
DOP2002000467A (es) * 2001-10-10 2003-04-15 Pfizer Prod Inc 2-amino-6 (fenilo sustituido en las posiciones 2,4,5)-piridinas
US6803470B2 (en) 2001-10-10 2004-10-12 Pfizer Inc 2-amino-6-(2,4,5-substituted-phenyl)-pyridines
US7045652B2 (en) 2002-07-03 2006-05-16 Pfizer Inc Processes for preparing substituted aryl boronic acids
US20040092741A1 (en) * 2002-11-08 2004-05-13 Pfizer Inc Substituted pyridines via boronic acid coupling
WO2005007627A1 (fr) * 2003-07-18 2005-01-27 Nihon Nohyaku Co., Ltd. Derive de phenylpyridine, produit intermediaire correspondant, et herbicide contenant ledit derive de phenylpyridine en tant qu'ingredient actif
US20080070952A1 (en) * 2005-02-21 2008-03-20 Proximagen Ltd., Inhibition or Treatment of Dyskinesia
GB0607196D0 (en) * 2006-04-11 2006-05-17 Prosidion Ltd G-protein coupled receptor agonists
AR064572A1 (es) * 2006-12-28 2009-04-08 Basf Ag Derivados de piridina 2-sustituidas, una composicion farmaceutica que las comprende y su uso en la preparacion de un medicamento para el tratamiento del cancer.
UA105182C2 (ru) 2008-07-03 2014-04-25 Ньюрексон, Інк. Бензоксазины, бензотиазины и родственные соединения, которые имеют ингибирующую nos активность
KR101735787B1 (ko) 2013-02-28 2017-05-16 주식회사 티움바이오 삼환식 화합물 및 이의 용도
EP3066072B1 (fr) * 2013-11-07 2021-11-03 The University of Kansas Inhibiteurs de hsp90 dérivés de biphénylamide
AR101510A1 (es) * 2014-08-13 2016-12-21 Meiji Seika Pharma Co Ltd Agentes anti-trichophyton cristalinos y proceso de preparación de los mismos
CN106265640B (zh) * 2016-08-11 2019-05-14 吉林大学 Appa在制备治疗糖尿病肾病药物中的应用
CN108069831B (zh) * 2018-01-25 2020-11-24 上海恩氟佳科技有限公司 一种合成2,3-二甲基-4-氟苯酚的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08504798A (ja) * 1992-12-18 1996-05-21 ザ ウエルカム ファウンデーション リミテッド 酵素阻害薬としての，ピリミジン，ピリジン，プテリジノンおよびインダゾール誘導体
KR100342275B1 (ko) * 1993-10-21 2002-12-05 지.디. 썰 엘엘씨 산화질소신타제저해제로서유용한아미디노유도체
AU4515696A (en) * 1994-12-12 1996-07-03 Merck & Co., Inc. Substituted 2-aminopyridines as inhibitors of nitric oxide synthase
UA49006C2 (uk) * 1996-03-29 2002-09-16 Файзер Інк. Похідні 6-фенілпіридил-2-аміну, фармацевтична композиція, спосіб інгібування синтази оксиду нітрогену у ссавців та спосіб лікування

Also Published As

Publication number Publication date
DE69825147D1 (de) 2004-08-26
YU35699A (sh) 2002-06-19
EP0958282A1 (fr) 1999-11-24
HN1998000030A (es) 1998-10-22
PE58599A1 (es) 1999-06-12
IL130898A0 (en) 2001-01-28
KR100460399B1 (ko) 2004-12-08
BG103633A (bg) 2000-11-30
UY24881A1 (es) 2000-12-29
AU744313B2 (en) 2002-02-21
AR011117A1 (es) 2000-08-02
TNSN98024A1 (fr) 2005-03-15
CZ276999A3 (cs) 2000-05-17
PA8446301A1 (es) 2000-05-24
JP3505189B2 (ja) 2004-03-08
OA11084A (en) 2002-03-15
PT958282E (pt) 2004-11-30
IS5118A (is) 1999-07-29
CA2277990A1 (fr) 1998-08-13
NO993823L (no) 1999-08-09
CN1246848A (zh) 2000-03-08
CO4920225A1 (es) 2000-05-29
HRP980069A2 (en) 1998-12-31
US20010007873A1 (en) 2001-07-12
WO1998034919A1 (fr) 1998-08-13
ZA981017B (en) 1999-08-10
GT199800032A (es) 1998-02-11
CA2277990C (fr) 2006-08-01
NO993823D0 (no) 1999-08-09
CN1515554A (zh) 2004-07-28
SK101199A3 (en) 2000-10-09
NO314803B1 (no) 2003-05-26
TR199901917T2 (xx) 1999-12-21
DZ2414A1 (fr) 2003-01-04
CN1523015A (zh) 2004-08-25
AP833A (en) 2000-05-10
UA64740C2 (uk) 2004-03-15
DK0958282T3 (da) 2004-11-29
EP0958282B1 (fr) 2004-07-21
CZ292135B6 (cs) 2003-08-13
EA199900632A1 (ru) 2000-02-28
TW458969B (en) 2001-10-11
JP2000509408A (ja) 2000-07-25
KR20000070803A (ko) 2000-11-25
AU5572798A (en) 1998-08-26
MY120976A (en) 2005-12-30
US20030162765A1 (en) 2003-08-28
EA003834B1 (ru) 2003-10-30
ES2224354T3 (es) 2005-03-01
HUP0000762A3 (en) 2000-10-30
SI0958282T1 (en) 2005-02-28
PL335161A1 (en) 2000-04-10
BR9811093A (pt) 2000-07-18
DE69825147T2 (de) 2005-08-04
HUP0000762A2 (hu) 2000-09-28
NZ336623A (en) 2000-11-24
NZ518345A (en) 2005-02-25
ATE271544T1 (de) 2004-08-15

Similar Documents

Publication Publication Date Title
MA26723A1 (fr) Acides oxamiques nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26697A1 (fr) Composes nouveaux inhibiteurs de gsk-3 et compositions pharmaceutiques les contenant
MA26733A1 (fr) Derives d'isothiazole nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA25035A1 (fr) Derives de 3-azabicyclo [3,1,0] hexane nouveaux, procede pour leur preparation et compositions les contenant
TNSN98024A1 (fr) 2-amino-6-(2-substitue-4-phenoxy)-substitue-pyridines, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26689A1 (fr) Derives de tetrahydroquinoleine substitues nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN97198A1 (fr) Derives de 6-phenylpyridyl-2- amine et compositions pharmaceutiques les contenant
MA26688A1 (fr) 4-carboxamino-2-substitue-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN97145A1 (fr) Derives 6,5-heterobicycliques substitues, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99253A1 (fr) Composes chimiques nouveaux modulateurs de ccr5, et compositions pharmaceutiques les contenant.
MA24729A1 (fr) Macrolides nouveaux.
TNSN99039A1 (fr) Bicyclo [2.2.1] heptanes nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99169A1 (fr) Derives de 4,4-biarylpiperidine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN98154A1 (fr) Derives de 2-aminopyridine nouveaux et compositions pharmaceutiques les contenant
TNSN98035A1 (fr) Atropisomeres de 3-aryl-4(3h)-quinazolinones, procede pour leur preparation et compositions les contenant
TNSN98036A1 (fr) Derives d'acide hexanoique nouveaux
MA26718A1 (fr) Derives de quinoleine-2-one a substituant heteroaryle nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26720A1 (fr) Composes nouveaux inhibiteurs de reabsorption de monoamines, procede pour leur preparation, et compositions pharmaceutiques les contenant.
TNSN97055A1 (fr) Derives de 6-phenylpyridyl -2- amine, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26696A1 (fr) Derives de tetrahydrobenzazepine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26729A1 (fr) Modulateurs nouveaux des recepteurs de glucocorticoides, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99031A1 (fr) Composes heterocycliques nouveaux inhibiteurs de romatases, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN98194A1 (fr) Derives nouveaux de 6-o-methylerythromycine a, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26690A1 (fr) COMPOSITIONS PHARMACEUTIQUES CONTENANT DES DERIVES DE PYRIDO [1,2-a ] PYRAZINE ET PROCEDE POUR LEUR PREPARATION
MA26701A1 (fr) PYRAZOLOPYRIMIDINONES NOUVELLES INHIBITRICES DE PDE-5 GMPc, PROCEDE POUR LEUR PREPARATION ET COMPOSTIONS PHARMACEUTIQUES LES CONTENANT.